China's NDRC Rumored To Cut Prices Of Brand-Name Primary Chinese Medicines
This article was originally published in PharmAsia News
China's National Development and Reform Commission is in discussions with provincial commodity price departments about cutting the prices of patent-protected essential Chinese drugs, such as Yunnan Baiyao, which constitute a large portion of drug makers' sales
You may also be interested in...
No device-related warning letters were released by the US FDA the week of 24 November.
Mooted some time ago, the Medicare Part D Drug Rebate Rule and the Medicare Part B Most-Favored-Nation Model have now been finalized by US President Donald Trump. But US off-patent body the Association for Accessible Medicines feels “further action is necessary.”
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.